Risk factor
Good trading liquidity
Profitability factor
Greatly overvalued vs peers
About
PharmaBlock Sciences (Nanjing), Inc. delivers a comprehensive suite of chemical products and specialized services, supporting the pharmaceutical industry across the full spectrum of its operations – from initial research and development phases to large-scale commercial production. The company's primary offerings encompass: A vast inventory of chemical building blocks, available for supply at every stage of drug creation, from early discovery through to advanced development and commercial manufacturing. The creation of diverse chemical libraries, derived from their building blocks, specifically designed to accelerate drug discovery processes. Contract development and manufacturing (CDMO) services for essential pharmaceutical components, including raw starting materials (RSMs), chemical intermediates, active pharmaceutical ingredients (APIs), and finished drug products, catering to both clinical development programs and market demands. Established in 2006, PharmaBlock Sciences maintains its corporate headquarters in Nanjing, People's Republic of China.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA
Target Price
The average target price of 300725.SZ is 47.0 and suggests 10.8% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommen